Foralumab is the first intranasal immune modulator in clinical trials for patients with Multiple System AtrophyBOSTON, May 14 ...

New data from IM1240 (capped-CD3 × 5T4 × NKG2A) tri-specific antibody demonstrated potent anti-tumor activity across all treatment-resistant ...

This week, Hach has revived the story to taunt LiPetri, who of the two is considered the insider in the Nassau County GOP ...

Multidimensional analyses demonstrate that repeated DeltEx DRI dosing preserves immune function, drives tumor microenvironment remodeling, and ...

EpCAM-targeted immunotherapies represent a key opportunity in treating epithelial tumors due to high expression in cancers but face challenges from off-tumor toxicities. Advances in conditional ...

SAB Biotherapeutics Inc (SABS) reports significant progress in its SAB142 program despite increased R&D and G&A expenses, maintaining a strong cash position to support future growth.

RAINIER is a multicenter, open-label, multi-cohort phase 1b/2 dose-optimization study enrolling adults aged 18 years or older ...

Therorna presents circRNA-based in vivo CAR-T, T-cell engager, and therapeutic cancer vaccine data at ASGCT 2026 in Boston.

Issued on behalf of GT Biopharma, Inc. Key Takeaways - First patient dosed in Phase 1 trial of GTB-5550, a B7-H3-targeted natural killer (NK) cell engager — the third TriKE® program to enter clinical ...

On March 20, the FDA approved Opdivo for adult and pediatric patients (aged 12 years and older) with previously untreated ...

Operator: Ladies and gentlemen, thank you for joining, and welcome to the Innate Pharma First Quarter 2026 Business Update and Financial Results.